A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Cognition Therapeutics
  • Most Recent Events

    • 20 Sep 2017 Status changed from active, no longer recruiting to completed, as reported in a Cognition Therapeutics media release
    • 07 Sep 2017 According to a Cognition Therapeutics media release, trial status will be discussed in the Mizuho Biotechnology Conference: CNS Deep Management Day and top-line results are expected to be announced in October 2017.
    • 31 Jul 2017 According to a Cognition Therapeutics media release, detailed results of this study are anticipated to be announced at the CTAD (Clinical Trials on Alzheimer's disease) meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top